

Tremfya (guselkumab)



METRO INFUSION CENTER

REFERRAL STATUS: ☐ New Referral ☐ Dose or Frequency Change ☐ Order Renewal
Infusion Office Preference: _____

PATIENT INFORMATION			
Date:	Patient Name:	DOB:	
<input type="checkbox"/> NKDA Allergies:	Weight (lbs / kg):		Height:
Patient Status: <input type="checkbox"/> New to Therapy <input type="checkbox"/> Continuing Therapy - Last Treatment Date:			Next Due Date:
PROVIDER INFORMATION			
Office Contact Name:		Office Email:	
Prescribing Providers Name:		Provider NPI:	
Office Address:	City:	State:	Zip:
Office Phone Number:		Office Fax Number:	
DIAGNOSIS AND ICD 10 CODE			
<input type="checkbox"/> Crohn's Disease	ICD-10 Code: K50.90		
<input type="checkbox"/> Ulcerative Colitis	ICD-10 Code: K51.90		
<input type="checkbox"/> Other Diagnosis:	ICD-10 Code:		
REQUIRED DOCUMENTATION/Testing			
<input type="checkbox"/> This signed order form by the provider <input type="checkbox"/> Patient demographics AND insurance info <input type="checkbox"/> Clinical/Progress notes supporting primary dx		<input type="checkbox"/> Confirmed negative TB testing <input type="checkbox"/> LFT Panel	
List Tried & Failed Therapies, including duration of treatment: 1) 2)			
MEDICATION ORDERS			
<input type="checkbox"/> Tremfya 200 mg IV at weeks 0 , 4 , 8			

SPECIAL INSTRUCTIONS

***Hepatotoxicity in treatment of Crohn's disease and Ulcerative Colitis. Drug induced liver injury has been reported. Monitor LFT's and bilirubin at baseline and during induction, up to at least 16 weeks of treatment. Monitor thereafter according to routine patient management.*

Provider Name (Print)

**Physician Signature:

Date:

Fax referral to 866-507-1164 or email to bionurses@metroinfusioncenter.com

All information contained in this order form is strictly confidential and will become part of the patient's medical record.